索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]隋利军,李维,甘建祥,等.托伐普坦对慢性心力衰竭急性发作合并利尿剂抵抗的疗效研究[J].国际心血管病杂志,2018,03:186-188.
点击复制

托伐普坦对慢性心力衰竭急性发作合并利尿剂抵抗的疗效研究(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2018年03期
页码:
186-188
栏目:
经验交流
出版日期:
2018-05-25

文章信息/Info

Title:
-
作者:
隋利军; 李维; 甘建祥; 郑亚国; 陈亮
214062 无锡市第九人民医院心内科(隋利军); 210006 南京市第一医院心内科(李维,甘建祥,郑亚国,陈亮)
Author(s):
-
关键词:
托伐普坦;  慢性心力衰竭;  利尿剂抵抗
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2018.03.016
文献标识码:
-
摘要:
目的:比较托伐普坦及托拉塞米对慢性心力衰竭(心衰)急性发作且合并利尿剂抵抗的疗效。方法:选择符合标准的慢性心衰急性发作患者70例,随机分为托拉塞米组及托伐普坦组,每组各35例。在常规药物治疗基础上,托拉塞米组予以静脉推注托拉塞米20 mg/d,托伐普坦组予以口服托伐普坦15 mg/d。比较治疗前后各项观察指标的变化。结果:与治疗前相比,治疗7 d后两组的体质量指数(BMI)、尿量、N末端脑钠肽前体(NT-proBNP)、血肌酐、心率及临床症状均有明显改善; 与托拉塞米组相比,托伐普坦组BMI、NT-pro
Abstract:
-

参考文献/References

[1] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology(ESC). Developed with the special contribution of the Heart Failure Association(HFA)of the ESC.[J]. Eur J Heart Fail, 2016, 18(8):891-975.
[2] Joseph SM, Cedars AM, Ewald GA, et al. Acute decompensated heart failure: contemporary medical management[J]. Tex Heart Inst, 2009, 36(6):510-520.
[3] Gheorghiade M, Follath F, Ponikowski P, et al. Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine[J]. Eur J Heart Fail, 2010, 12(5):423-433.
[4] Koeda C, Yamaya S, Hozawa M, et al. Comparison of the effects of carperitide and tolvaptan on patients with left ventricular dysfunction: a two-center retrospective study[J]. Cardiol Res Pract, 2017, 2017:6935342.
[5] Dohi K, Ito M. Novel diuretic strategies for the treatment of heart failure in Japan[J]. Circ J, 2014, 78(8):1816-1823.
[6] Peri A. Clinical review: the use of vaptans in clinical endocrinology[J]. J Clin Endocrinol Metab, 2013, 98(4):1321-1332.
[7] Taylor SH. Diuretics threapy in congestive heart failure[J]. Cardiol Rev, 2000, 8(2):104-114.
[8] Matsue Y, Ter Maaten JM, Suzuki M, et al. Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction[J]. Clin Res Cardiol, 2017, 106(10):802-812.
[9] Zulkifli Amin H, Suridanda Danny S. Tolvaptan: a novel diuretic in heart failure management[J]. J Tehran Heart Cent, 2016, 11(1):1-5.
[10] Pang PS, Gheorghiade M, Dihu J, et al. Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan(Everest)trials[J]. Am Heart J, 2011, 161(6):1067-1072.
[11] Gheorghiade M, Orlandi C, Burnett JC, et al. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan(EVEREST)[J]. J Card Fail, 2005, 11(4):260-269.
[12] Udelson JE, Orlandi C, Ouyang J, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial[J]. J Am Coll Cardiol, 2008, 52(19):1540-1545.
[13] Udelson JE, Mcgrew FA, Flores E, et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction[J]. J Am Coll Cardiol, 2007, 49(22):2151-2159.
[14] Matsue Y, Suzuki M, Torii S, et al. Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction[J]. J Card Fail, 2016, 22(6):423-432.

备注/Memo

备注/Memo:
通信作者:陈亮,Email:windcloud82@163.com
更新日期/Last Update: 2018-06-01